TILs, including CD8+ T and NK cells that are central to anti-tumor immunity in breast cancer, have prognostic significance even in systemically untreated early TNBC, suggesting that the presence of TILs may delineate candidates most likely to benefit from adjuvant chemotherapy or immunotherapy (74). This evidence concerns the gene CD8A and breast carcinoma.